Chronic myeloid leukemia harboring T315I and F317L mutations successfully treated with interferon-α and ponatinib

DOI Web Site PubMed

Bibliographic Information

Other Title
  • Interferon-αおよびponatinibが奏効したT315I, F317L変異を有する慢性骨髄性白血病
  • 症例報告 第8回日本血液学会関東甲信越地方会 優秀演題 Interferon-αおよびponatinibが奏効したT315I,F317L変異を有する慢性骨髄性白血病
  • ショウレイ ホウコク ダイ8カイ ニホン ケツエキ ガッカイ カントウ コウシンエツチホウカイ ユウシュウ エンダイ Interferon-a オヨビ ponatinib ガ ソウコウ シタ T315I,F317L ヘンイ オ ユウスル マンセイ コツズイセイ ハッケツビョウ

Search this article

Abstract

<p>Our patient was diagnosed with chronic myeloid leukemia (CML) in chronic phase (CP) when he was 40 years old. Although dasatinib (DAS) was prescribed during his clinical course, he was poorly compliant with the treatment. In November 20XX, at 65 years of age, he visited our hospital with leukocytosis. He was diagnosed with CML in CP and recommenced DAS at 50 mg/day, achieving a complete hematological response after 2 months. However, DAS was increased to 100 mg/day because only minimum cytogenetic response was evident even after 9 months, but CML progressed to the accelerated phase after 18 months. The ABL kinase domain mutations T315I and F317L were detected. Ponatinib (PON) was not yet approved, and he declined allogeneic stem cell transplantation therapy. He commenced interferon-α (IFN-α) in addition to DAS, and the F317L mutation (only) disappeared after 7 months; the patient achieved a major cytogenetic response. In January 20XX＋4, he commenced PON monotherapy (the drug was approved by this time) and achieved a major molecular response after 8 months. The T315I mutation disappeared during PON therapy. Although IFN-α is rarely used in the treatment of CML, this case suggests that IFN-α should be re-considered in patients with CML who exhibit tyrosine kinase inhibitor resistance.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 60 (1), 33-38, 2019

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top